Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MRK files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMerck shareholders re-elect all 13 directors, approve executive pay at annual meeting
Filed May 28, 2026 · Period ending May 26, 2026 · ~1 min read
Key Changes
-
low
All 13 director nominees elected to Merck's board with strong support, votes ranging from 1.6 to 1.8 billion shares in favor; Patricia Russo received lowest support at 88% approval.
Item 5.07 verify on EDGAR → -
low
Executive compensation approved in non-binding say-on-pay vote with 94% shareholder support (1.73 billion for vs. 109 million against), indicating satisfaction with pay practices.
Item 5.07 verify on EDGAR → -
low
Independent auditor appointment ratified for 2026 with 94% approval, confirming continuity in external audit relationships.
Item 5.07 verify on EDGAR → -
low
Three shareholder proposals overwhelmingly rejected, including DEI risks report (1% support), healthcare coverage gaps (1% support), and political contributions disclosure (12% support).
Item 5.07 verify on EDGAR →
Summary
Merck held its 2026 annual shareholder meeting on May 26, with voting results indicating strong alignment between shareholders and management. All 13 director nominees were re-elected with substantial support, executive compensation received a 94% approval rating in the advisory vote, and the independent auditor was ratified for another year.
Three shareholder proposals seeking additional disclosures on DEI risks, healthcare coverage, and political contributions were decisively rejected with minimal support. For retail investors, this filing represents routine corporate governance with no material changes to Merck's leadership or strategic direction.
The strong support for management's positions and the board slate suggests shareholders are satisfied with the company's current trajectory. The rejection of shareholder proposals indicates the board's existing disclosure practices are deemed sufficient by the majority of investors. Watch for Merck's next quarterly earnings report and any updates on its drug pipeline, as those will provide more meaningful insights into the company's operational performance and future prospects than these procedural governance matters.
Section-by-Section Diff
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Merck held its 2026 annual shareholder meeting on May 26, electing 13 directors and approving executive compensation and auditor ratification.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
The following nominees were elected to the Company’s Board of Directors to hold office until the Company’s next Annual Meeting of Shareholders
All 13 director nominees were elected to Merck's Board, with votes ranging from approximately 1.6 billion to 1.8 billion shares in favor. Patricia F. Russo received the lowest support with 1,636,745,520 votes for and 217,186,188 against, while Douglas M. Baker, Jr. received the highest support with 1,849,536,622 votes for.
Added in current filing · verify on EDGAR →
Ratification of the appointment of the Company’s independent registered public accounting firm for 2026: 2,011,579,504votes FOR 126,487,980votes AGAINST
Shareholders ratified the appointment of Merck's independent auditor for 2026 with approximately 94% support (2.01 billion for vs. 126 million against). This routine approval confirms continuity in external audit relationships.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 28, 2026 · How we verify